Ideaya goes forward with $150M offering after touting PhII cancer data

Tyler Patchen

News Reporter

Ideaya Biosciences has lifted the cover on some data for its metastatic uveal melanoma (MUM) treatment while also forging ahead with an offering of its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ideaya goes forward with $150M offering after touting PhII cancer data

Tyler Patchen

News Reporter

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

Ideaya goes for­ward with $150M of­fer­ing af­ter tout­ing PhII can­cer da­ta

Tyler Patchen

News Reporter

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Ideaya goes forward with $150M offering after touting PhII cancer data

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?